Skip to content
World of Video Gaming – Lifestyle
Home
Sample Page
Author:
ELI LILLY AND COMPANY
Foundayo and Zepbound now covered for millions of Americans
May 28, 2026
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
Lilly announces three acquisitions to build infectious disease portfolio
May 26, 2026
A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
May 25, 2026
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
May 22, 2026
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
May 21, 2026
Lilly to participate in Bernstein’s 42nd Annual Strategic Decisions Conference
May 18, 2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 16, 2026
Lilly and UNICEF collaborate to give millions of children a healthier start
May 14, 2026
Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
May 13, 2026
←
Previous Page
1
2
3
4
Next Page
→